Se describe el caso de un paciente VIH positivo con lesiones orales provocadas por el virus del herpes en el contexto del síndrome de reconstitución inmune secundario a la terapia antirretroviral de gran actividad.

---

Bibliografía del caso clínico
1. Garber KA, Weathers DR. Three cases of Acquired immune deficiency syndrome (AIDS) with oral manifestations. Compendium 6(97-100):104-5, 1985.
2. Phelan JA, Freedman PD. Oral manifestations of acquired immunodeficiency syndrome (AIDS) and HLVV( LAV) infection. NX J Dent 56:176, 1986.
3. Pindborg JJ, Schiodt M, Colstrip P. Oral lesions in patients with HIV infection. Tandlaegehladet 92:405-4, 1988.
4. Epstein JB, Silverman S. Oral manifestations of Human immune deficiency virus infection. Recognition and diagnosis. J Can Dent Assoc 54:413-9, 1988.
5. Jordan RCK, Main JHP. The oral manifestations of HIV infection. Can Dent Assoc J 57:59-61, 1991.
6. Greenspan D, Greenspan J, Pindborg JJ, et al. Oral manifestations of infection diseases. In: AIDS and the Dental Team, Copenhagen Munksgaard pp. 35-61, 1986.
7. Casariego Z, Cahn P, Pérez H, Casiró A, Muchinik G, Rickard E. Oral pathology is a good predictor for HIV infection in high risk population. Int Conf AIDS 6:207, 1990.
8. Barr CE, Torosian JP. Oral manifestations in patients with AIDS or AIDS-related complex. Lancet 2:288, 1986.
9. Ficarra G, Lozada-Nur F, Greenspan D, Hansen LS, Green TL. Síndrome de inmunodeficiencia acquisita (AIDS): lesión del cavo orale. (Acquire immunodeficiency syndrome (AIDS): lesions in the mouth). Mondo Odontoestomatol 28:17-26, 1986.
10. Eyeson JD, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KA. Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. J Oral Pathol Med 31(3):169-74, 2002.
11. Ramírez Amador V, Esquivel Pedraza L, Sierra Madero J, Anaya Saavedra G, González Ramírez I, Ponce de León S. The changing clinical spectrum of human immunodeficiency virus (HIV) related oral lesions in 1.000 consecutive patients: A 12-year study in a referral center in Mexico. Medicine (Baltimore) 82(1):39-50, 2003.
12. The Phuket Declaration on Oral Health in HIV/AIDS 2004. Oral Diseases 11: 1-2, 2005.
13. Casariego Z, Ben G. Manifestaciones bucales de la infección por VIH en Argentina: estudio de 1889 casos. Medicina Oral 3(5):271-76, 1998.
14. Casariego ZJ, Herrero T, Pombo T. Estudio inmunohistoquímico de úlceras aftosas recidivantes (RAU) en dos subpoblaciones: pacientes RAU+(VIH-), RAU+ (VIH+), versus RAU/VIH+ y población control RAU-/VIH. Avances en Odontoest 17(8):399-418, 2001.
15. Bagán Sebastián JV, Milian Masanet A, Lloria de Miguel E, Cardona Tertajada F, Jiménez Soriano Y. Infecciones por virus del herpes. Medicina Oral 2(1):54, 1997.
16. Rivarola de Gutiérrez de Parra N, Tonelli de Aguinaga MEI. Citología exfoliativa de la mucosa bucal. Rev Asoc Odontol Argent 87(4/5):331-35, 1999.
17. Jawetz E, Melnick JL, Adelberg EA. Herpes virus. En Microbiología Médica XIV ed. El Manual Moderno, México, pp. 451-464, 1992.
18. Marco MM, Grasa Jordan MP, Carapeto Márquez del Prado FJ. Inmunohistoquímica: análisis crítico. Piel 13:93-98, 1988.
19. Miró JM, Martínez Chamorro E, Peña JM. Restauración inmunológica y tratamiento antirretroviral de gran actividad (TARGA). En: Avances en el manejo del paciente infectado por HIV. Podzcamer D. Ed. team Pharma, Madrid, pp. 152-170, 1999.
20. Stoll M, Schmith RE. Immune restoration inflammatory syndrome the dark side of ssucceful antiretroviral therapy. Curr Infect Dis Rep 5:266-276, 2003.
21. Shelburne SA III, Hamill RJ, Rodríguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al. Immune reconstitution inflammatory syndrome: emergence a unique syndrome during highly active retroviral therapy. Medicine (Baltimore) 81:213-227, 2002.
22. De Simone JSA, Pomerants RJ, babichak TJ. Inflammatory reactions in HIV-1 infected persons alter initiation of highly active antiretroviral therapy. Ann Intern Med 133:447-454, 2000.
23. Robinson MR, Csaky KG, Lee SS, Masur H, Polis MA. Fibrovascular changes misdiagnosed as CMV retinitis reactivation on a patient with immune recovery. Clin Infect Dis 38:139-141, 2004.
24. Aldeen T, Hay P, Davidnson F, Lau R. Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy. AIDS 12:1719-1720, 1998.
25. Greenspan D, Canchola AJ, Mac Phail LA, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 357:1411-1412, 2001.
26. Hoffman C, Horst HA, Albrecht H, Sdhlote W. Progressive multifocal leucoencephalophaty with unusual inflammatory response during antiretroviral therapy for human immunodeficiency virus infection. Clin Infect Dis 36:1191-1194, 2003.
27. Proia A, Ngui SL, Kaur S, Kessler HA, Trenhome GM. Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy. Am J Med 108:249-251, 2000.
28. Leigh JE, Shetty K, Fidel PL jr. Oral opportunistic infections in HIV-positive individuals: review and role of mucosal immunity. AIDS Patient care STDS 18(8):443-56, 2004.
30. Trevani A, Giordano M, Salamone G, Vermeulen M, Gamberréale R,Geffener JR. Modulación de la actividad del neutrófilo en el foco inflamatorio. Mecanismos moleculares involucrados. En: Rabinovich GA. Inmunopatología molecular: nuevas fronteras en la medicina. Buenos Aires Médica Panamericana 240-43, 2004.
31. Silverstein Roy L. The vascular endothelium, endothelial cell responses to pathologic agents. En: Gallin JI, Snyderman R. Inflammation: basic correlates, 3rd ed. Edited by Lippincott Willians & Willkins, Philadelphia pp. 213-214, 1999.
32. Massouth EJ, Benencia F. Inmunidad innata frente al virus herpes. En: Rabinovich GA. Inmunopatología molecular: nuevas fronteras en la medicina. Buenos Aires Médica Panamericana 240-43, 2004.
33. Stone SF, Price P, Brochier J, French MA. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpes virus-associated immune restoration desease after start of highly active antiretroviral therapy. J Infect Dis 184:1073-1077, 2001.
34. Richardson AR, Libby SJ, Fang FC. A Nitric oxide-inducible lactate dehydrogenase enables Staphylococcus aureus to resist innate. Immunity 319(5870):1672-76, 2008.

Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.